Actively Recruiting
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-01-21
2000
Participants Needed
5
Research Sites
1513 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.
CONDITIONS
Official Title
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with esophageal or esophagogastric cancer
- Histologically confirmed squamous cell carcinoma or adenocarcinoma staged I-IVa (AJCC 8th edition)
- Primary treatment performed at Cancer Hospital, Chinese Academy of Medical Sciences
- ECOG performance status score of 0 or 1
- Estimated survival time of at least 3 months
- Normal organ and marrow function as defined by specified blood and chemistry values
- Provided informed consent
You will not qualify if you...
- Presence of distant metastasis outside regional lymph nodes or in liver, lung, bone, CNS, etc.
- History of other cancers within the past 5 years except cervical carcinoma in situ or non-malignant melanoma skin cancer
- Active infections such as tuberculosis or hepatitis
- History of myocardial infarction within 6 months or ventricular arrhythmia
- Uncontrolled illnesses including active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness
- Allergic reactions to paclitaxel, albumin, or cisplatin
- Current or recent participation in other clinical trials within 4 weeks
- Pregnant or breastfeeding females
- Lack of medical records
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Department 4th of Radiation Oncology, Anyang Cancer Hospital
Anyang, Henan, China, 455001
Actively Recruiting
2
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, Hunan, China, 410031
Actively Recruiting
3
Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210009
Actively Recruiting
4
Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
5
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, China, 100021
Actively Recruiting
Research Team
X
Xin Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here